Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

Candel Therapeutics (CADL) FCF Margin (2020 - 2023)

Candel Therapeutics' FCF Margin history spans 4 years, with the latest figure at 1167.9% for Q4 2023.

  • For Q4 2023, FCF Margin rose 2426790.0% year-over-year to 1167.9%; the TTM value through Dec 2023 reached 1337.23%, up 2772110.0%, while the annual FY2024 figure was 1293.73%, 263096.0% down from the prior year.
  • FCF Margin for Q4 2023 was 1167.9% at Candel Therapeutics, down from 1273.54% in the prior quarter.
  • Across five years, FCF Margin topped out at 1787.36% in Q1 2023 and bottomed at 95700.0% in Q4 2021.
  • The 4-year median for FCF Margin is 18867.74% (2021), against an average of 19499.11%.
  • The largest annual shift saw FCF Margin plummeted -8175161bps in 2021 before it skyrocketed 7260000bps in 2022.
  • A 4-year view of FCF Margin shows it stood at 13948.39% in 2020, then tumbled by -586bps to 95700.0% in 2021, then soared by 76bps to 23100.0% in 2022, then skyrocketed by 105bps to 1167.9% in 2023.
  • Per Business Quant, the three most recent readings for CADL's FCF Margin are 1167.9% (Q4 2023), 1273.54% (Q3 2023), and 1154.66% (Q2 2023).